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Background: There have been several reports that statin therapy is associated with a
slightly higher incidence of new-onset diabetes mellitus(DM) or impaired glucose
intolerance(IGT). It is still controversial whether the chronic statin therapy is a risk factor
of IGT and new onset DM, in Asian population.
Methods: We investigated the 13,561 patients(pts) that was HbA1c level 6.0% and
fasting glucose level124 mg/dL(statin therapy group4016 and control group9545).
To adjust potential confounders including age, gender, hypertension, hyperlipidemia,
chronic kidney disease, hyper/hypo-thyroidism, lipid profile, beta-blocker, diuretics, a
propensity score matched analysis was performed using the logistic regression model. The
primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired
fasting glucose(IFG). Also, Multivariable Cox-regression analysis adjusted aforemen-
tioned variables was performed to determine the impact of statin therapy on the incidence
of new-onset DM, IGT, and IFG.
Results: Mean follow-up duration was 534604 days in all group, and 608607 days
in propensity score matching group. Baseline characteristics was similar between the two
groups except hyperlipidemia (11.1% vs. 3.5%, p0.001). In Kaplan-Meyer curve, there
was no difference between the two groups (p0.501, figure A). Also, in cox-regression
analysis performed in all pts, statin therapy was not associated with the increased
incidence of primary end-point(figure B).
Conclusions: In our study, there was no clear association with statin therapy and IGT and
new-onset DM in a series of cardiovascular pts in Asian population.
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Background: Introduction Few data is available on the comparison between diabetic and
non-diabetic patients after percutaneous coronary intervention (PCI) with drug eluting
stents for unprotected left main coronary artery disease. Hypothesis We assessed the
hypothesis that diabetes mellitus is a predictor of worse clinical outcome after PCI with
drug eluting stents for unprotected left main disease.
Methods: This is a multicenter registry enrolling consecutive patients undergoing PCI
with paclitaxel or everolimus-eluting stents for unprotected left main disease. Death,
cardiac death, myocardial infarction (MI), clinically-driven-target lesion revascularization
(TLR), target vessel revascularization (TVR), stroke, definite/probable stent thrombosis
were assessed at 2-year follow-up. A multiple cox regression analysis was performed.
Hazard ratios (HR) with 95% confidence interval (CI) were calculated.
Results: A total of 331 patients, median age 71 yrs-old, (25th-75th percentile 62-78), 87
(26.3%) diabetics, 172 undergoing paclitaxel eluting stent and 159 undergoing everolimus
eluting stent implantation, were enrolled. At 2-year follow-up diabetics, as compared to
non-diabetic patients, presented a higher incidence of death (14.9% vs 4.5%, p0.001),
cardiac death (9.2% vs 2.9%, p0.015), stroke (5.7% vs 0.8%, p0.015), definite/probable
stent thrombosis (3.4% vs 0%, p0.018), the composite of death/MI/stroke, (21.8% vs 9.8%,
p0.004), the composite of death/MI/TLR (22.9% vs 13.1%, p0.03), and the composite of
death/MI/TLR/stroke (25.3% vs 13.5%). No significant differences between diabetics and
non-diabetic patients were found with respect to MI (10.3% vs 6.1%, p0.19), TLR (6.9% vs
4.9%, p0.48) or TVR (16.1% vs 9.4%, p0.09). At multiple cox regression analysis,
diabetes status was a significant predictor of death/MI/stroke (HR 2.39, 95% CI 1.30-4.37,
p0.005), of death/MI/TLR (HR 1.97, 95% CI 1.12-3.46, p0.018) and of death/MI/TLR/
stroke (HR 2.08, 95% CI 1.21-3.58, p0.008).
Conclusions: In patients undergoing PCI with drug eluting stents for unprotected left
main coronary artery disease, diabetes status is associated with a significantly worse
prognosis at 2-year follow-up.
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Background: Plain Old Balloon Angioplasty (POBA) for In-Stent Restenosis (ISR) in
the superficial femoral artery (SFA) and proximal popliteal artery (PA) has a recurrent
stenosis rate of up to 70% within 12 months. Aim of the study was to test the ability to
reduce this high recurrency rate with a Paclitaxel Eluting Balloon (PEB).
Methods: Since January 2010, 44 consecutive patients with symptomatic in-stent restenosis
of the SFA or proximal PA were treated with PEB (Admiral In.Pact, Medtronic, Minnesota,
USA). The occurrence of re-restenosis and repeat intervention at 1-year follow up was
compared to those of 42 consecutive patients treated with POBA from January 2008 to
December 2009.
Results: No significant difference in terms of clinical, angiographic and procedural charac-
teristics were observed among the two study groups. Respectively: Age 7411 in PEB vs
767 in POBA, P0.1; insuline therapy 23/44(50%) vs 21/42(48%), p0.9; Rutherford
Class4 33/44(75%) vs 28/42(67%), p0.8; serum creatinine 1.091.5mg/dL vs
1.021.5mg/dL, p0.9; occlusive ISR 23/44(52%) vs 28/42(66%), p0.1; restenosis length
13186mm vs 13885mm, p0.4. Procedural success, defined as a residual stenosis 30%
in the restenotic segment (stent	5mm of proximal and distal edges), was obtained in all treated
lesions and no adverse clinical events occurred during hospitalization in both groups. At
one-year follow-up, 6 patients died (3 in PEB and 3 in POBA), one patient in POBA group
underwent major amputation. Restenosis, assessed by angiography or ultrasound, occurred in
8/41(19%) PEB vs 28/39(72%) POBA, p0.05. Repeat angioplasty for symptomatic in stent
re-restenosis occurred in 6/44(13%) PEB vs 13/42(31%) POBA, p0.05.
Conclusions: Repeat balloon angioplasty for ISR in the SFA and proximal PA artery
using PEB showed a significant reduction in re-restenosis and repeat angioplasty
compared to POBA at 1-year follow-up.
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Background: Diabetic patients (DP) show more complex coronary artery disease than
non-diabetic patients (N-DP) and diabetes mellitus (DM) predicts adverse outcome after
MI. We sought to investigate the interaction of reperfusion and DM on mortality after
STEMI treated with primary PCI.
Methods: A multicenter registry of consecutive patients treated with primary PCI in 3
centers. Vital status was obtained through municipality records. Reperfusion was scored
by TIMI flow. Cox regression was used to analyze effect modification of the correlation
between sub-optimal reperfusion (TIMI3) and mortality by DM.
Results: In total, 386 DP and 3063 N-DP were treated with primary PCI. DP were older
(66.7 vs. 62.8 years in N-DP, p0.001), less often male (68.4% vs. 75.9% in N-DP,
p0.001), more frequently suffered a previous MI (14.3% in DP vs. 10.3% N-DP,
p0.018) and renal insufficiency (12.5% vs. 2.6% in N-DP, p0.001). Moreover, DP
showed more multi-vessel disease (31.3% vs. 20.3% in N-DP, p0.001). TIMI flow
before and after PCI was similar. Mortality was higher in DP (30 day: 9.1% vs. 3.8% in
N-DP, p0.001, 1 year: 14.5% in DP vs. 6.1% in N-DP, p0.001). Furthermore, DP
patients showed substantially worse 1 year mortality after sub-optimal reperfusion
compared to N-DP (figure), an interaction which was confirmed by cox regression
(interaction HR 2.36, 95% CI 1.11-5.03 after correction for confounders).
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